Literature DB >> 16095998

Molecular mechanisms in gliomagenesis.

Esther Hulleman1, Kristian Helin.   

Abstract

Glioma, and in particular high-grade astrocytoma termed glioblastoma multiforme (GBM), is the most common primary tumor of the brain. Primarily because of its diffuse nature, there is no effective treatment for GBM, and relatively little is known about the processes by which it develops. Therefore, in order to design novel therapies and treatments for GBM, research has recently intensified to identify the cellular and molecular mechanisms leading to GBM formation. Modeling of astrocytomas by genetic manipulation of mice suggests that deregulation of the pathways that control gliogenesis during normal brain development, such as the differentiation of neural stem cells (NSCs) into astrocytes, might contribute to GBM formation. These pathways include growth factor-induced signal transduction routes and processes that control cell cycle progression, such as the p16-CDK4-RB and the ARF-MDM2-p53 pathways. The expression of several of the components of these signaling cascades has been found altered in GBM, and recent data indicate that combinations of mutations in these pathways may contribute to GBM formation, although the exact mechanisms are still to be uncovered. Use of novel techniques including large-scale genomics and proteomics in combination with relevant mouse models will most likely provide novel insights into the molecular mechanisms underlying glioma formation and will hopefully lead to development of treatment modalities for GBM.

Entities:  

Mesh:

Year:  2005        PMID: 16095998     DOI: 10.1016/S0065-230X(05)94001-3

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  27 in total

1.  Malignant and benign ganglioglioma: a pathological and molecular study.

Authors:  Ajay Pandita; Anandh Balasubramaniam; Richard Perrin; Patrick Shannon; Abhijit Guha
Journal:  Neuro Oncol       Date:  2007-01-26       Impact factor: 12.300

2.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

3.  Differential and kinetic effects of cell cycle inhibitors on neoplastic and primary astrocytes.

Authors:  Veetai Li; Thomas J Langan; Kyla R Rodgers; Richard C Chou
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

4.  Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.

Authors:  Jie Chen; Santosh Kesari; Christine Rooney; Peter R Strack; Jihua Chen; Huangxuan Shen; Lizi Wu; James D Griffin
Journal:  Genes Cancer       Date:  2010-08

Review 5.  The bright and the dark sides of DNA repair in stem cells.

Authors:  Guido Frosina
Journal:  J Biomed Biotechnol       Date:  2010-04-08

6.  RNAi-induced synthetic lethality in cancer therapy.

Authors:  Bingbing Dai; Bingliang Fang; Jack A Roth
Journal:  Cancer Biol Ther       Date:  2009-12-06       Impact factor: 4.742

7.  HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration.

Authors:  Rosaria Bassi; Paola Giussani; Viviana Anelli; Thomas Colleoni; Marco Pedrazzi; Mauro Patrone; Paola Viani; Bianca Sparatore; Edon Melloni; Laura Riboni
Journal:  J Neurooncol       Date:  2007-11-02       Impact factor: 4.130

Review 8.  Adenoviral virotherapy for malignant brain tumors.

Authors:  Suvobroto Nandi; Maciej S Lesniak
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

9.  Cause and consequences of genetic and epigenetic alterations in human cancer.

Authors:  B Sadikovic; K Al-Romaih; J A Squire; M Zielenska
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

10.  Identification of proteins involved in neural progenitor cell targeting of gliomas.

Authors:  Karin Staflin; Thole Zuchner; Gabriella Honeth; Anna Darabi; Cecilia Lundberg
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.